| Autor: |
Peeney D; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Gurung S; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Rich JA; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Coates-Park S; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Liu Y; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Toor J; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Jones J; Center for Cancer Research Protein Expression Laboratory, National Cancer Institute, Frederick, MD, USA., Richie CT; Genetic Engineering and Viral Vector Core, Office of the Scientific Director, National Institute on Drug Abuse, Baltimore, MD, USA., Jenkins LM; Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Stetler-Stevenson WG; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. |
| Abstrakt: |
Classical methods of investigating protein-protein interactions (PPIs) are generally performed in non-living systems, yet in recent years new technologies utilizing proximity labeling (PL) have given researchers the tools to explore proximal PPIs in living systems. PL has distinct advantages over traditional protein interactome studies, such as the ability to identify weak and transient interactions in vitro and in vivo. Most PL studies are performed on targets within the cell or on the cell membrane. We have adapted the original PL method to investigate PPIs within the extracellular compartment, using both BioID2 and TurboID, that we term extracellular PL (ePL). To demonstrate the utility of this modified technique, we investigate the interactome of the widely expressed matrisome protein tissue inhibitor of metalloproteinases 2 (TIMP2). Tissue inhibitors of metalloproteinases (TIMPs) are a family of multi-functional proteins that were initially defined by their ability to inhibit the enzymatic activity of metalloproteinases (MPs), the major mediators of extracellular matrix (ECM) breakdown and turnover. TIMP2 exhibits a broad expression profile and is often abundant in both normal and diseased tissues. Understanding the functional transformation of matrisome regulators, like TIMP2, during the evolution of tissue microenvironments associated with disease progression is essential for the development of ECM-targeted therapeutics. Using carboxyl- and amino-terminal fusion proteins of TIMP2 with BioID2 and TurboID, we describe the TIMP2 proximal interactome. We also illustrate how the TIMP2 interactome changes in the presence of different stimuli, in different cell types, in unique culture conditions (2D vs 3D), and with different reaction kinetics (BioID2 vs. TurboID); demonstrating the power of this technique versus classical PPI methods. We propose that the screening of matrisome targets in disease models using ePL will reveal new therapeutic targets for further comprehensive studies. |
